Enlivex Therapeutics (ENLV) Earnings Date, Estimates & Call Transcripts $1.43 +0.08 (+5.93%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$1.46 +0.03 (+1.75%) As of 08/8/2025 06:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Enlivex Therapeutics Earnings Summary Enlivex Therapeutics posted Q1 2025 earnings on May 30, 2025, reporting an EPS of -$0.15, which beat analysts' consensus estimates of -$0.16 by $0.01. With a trailing EPS of -$0.66, Enlivex Therapeutics' earnings are expected to grow next year, from ($0.70) to ($0.58) per share. Q1 2025 Earnings ResourcesQ1 2025 Earnings ReportENLV Upcoming EarningsEnlivex Therapeutics' Q1 2025 earnings is scheduled for Friday, August 29, 2025Upcoming Q2 Earnings DateAug. 29Before Market OpensEstimatedConsensus EPS (May. 30) -$0.16 Actual EPS (May. 30) -$0.15 Beat By $0.01 Get Enlivex Therapeutics Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Enlivex Therapeutics and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataENLV Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter. Enlivex Therapeutics Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20251-$0.16-$0.16-$0.16Q2 20251-$0.16-$0.16-$0.16Q3 20251-$0.14-$0.14-$0.14Q4 20251-$0.13-$0.13-$0.13 Enlivex Therapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame Start Date End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails 8/29/2025(Estimated)--------5/30/2025Q1 2025-$0.16-$0.15+$0.01-$0.15--3/31/2025Q4 2024-$0.16-$0.23 -$0.07-$0.23--11/29/2024Q3 2024-$0.16-$0.12+$0.04-$0.12--8/30/2024Q2 2024-$0.22-$0.16+$0.06-$0.16--6/14/2024Q1 2024-$0.25-$0.22+$0.03-$0.22--3/29/2024Q4 2023--$0.48--$0.48--11/9/2023Q3 2023-$0.32-$0.32--$0.32--9/1/2023Q2 2023-$0.43-$0.37+$0.06-$0.37-- Enlivex Therapeutics Earnings - Frequently Asked Questions When is Enlivex Therapeutics' earnings date? Enlivex Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Friday, August 29th, 2025 based off last year's report dates. Learn more on ENLV's earnings history. Did Enlivex Therapeutics beat their earnings estimates last quarter? In the previous quarter, Enlivex Therapeutics (NASDAQ:ENLV) reported ($0.15) earnings per share (EPS) to beat the analysts' consensus estimate of ($0.16) by $0.01. Learn more on analysts' earnings estimate vs. ENLV's actual earnings. How much profit does Enlivex Therapeutics generate each year? Enlivex Therapeutics (NASDAQ:ENLV) has a recorded net income of -$15.01 million. ENLV has generated -$0.66 earnings per share over the last four quarters. What is Enlivex Therapeutics' EPS forecast for next year? Enlivex Therapeutics' earnings are expected to grow from ($0.70) per share to ($0.58) per share in the next year. More Earnings Resources from MarketBeat Related Companies Genelux Earnings Results Compugen Earnings Results Korro Bio Earnings Results Spero Therapeutics Earnings Results BioHarvest Sciences Earnings Results Fate Therapeutics Earnings Results Seres Therapeutics Earnings Results Immuneering Earnings Results Protalix BioTherapeutics Earnings Results Inhibikase Therapeutics Earnings Results Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Airbnb Beats Earnings, But the Growth Story Is Losing AltitudeDutch Bros Just Flipped the Script With a Massive Earnings BeatIs Eli Lilly’s 14% Post-Earnings Slide a Buy-the-Dip Opportunity?Constellation Energy’s Earnings Beat Signals a New EraRealty Income Rallies Post-Earnings Miss—Here’s What Drove ItDon't Mix the Signal for Noise in Super Micro Computer's EarningsWhy Monolithic Power's Earnings and Guidance Ignited a Rally This page (NASDAQ:ENLV) was last updated on 8/11/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enlivex Therapeutics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Enlivex Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access Sale